{"podcast":{"title":"Decera Clinical Education Oncology Podcast","slug":"decera-clinical-education-oncology-podcast-1302999","podcast_index_feed_id":1302999,"rss_url":"https://feeds.simplecast.com/GlfUTtJq","website_url":"https://oncologypodcast.simplecast.com","image_url":"https://image.simplecastcdn.com/images/ec61b327-3a4f-4bed-a4d2-7c7d2df62891/2d9bf1a9-d5c4-4079-9b3e-a531bfcf7774/3000x3000/decera-onc-podcast-show-icon.jpg?aid=rss_feed","author":"Decera Clinical Education","episode_count":253,"summary":"Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.","last_synced_at":"2026-07-15T02:18:52.844818+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999"},"episode":{"title":"What Oncology Pharmacists Need to Know About Targeting BCMA in Early Relapsed/Refractory Myeloma","slug":"what-oncology-pharmacists-need-to-know-about-targeting-bcma-in-early-relapsed-refractory-myeloma","published_at":"2026-07-13T19:28:33+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/what-oncology-pharmacists-need-to-know-about-targeting-bcma-in-early-relapsed-refractory-myeloma","show_page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999","url":"https://oncologypodcast.simplecast.com/episodes/what-oncology-pharmacists-need-to-know-about-targeting-bcma-in-early-relapsed-refractory-myeloma-LttbW4Ku","audio_url":"https://afp-928689-injected.calisto.simplecastaudio.com/1d8e143b-904e-45be-b6c5-8fba793d9d74/episodes/b64fab67-3153-4fd2-acd7-41f917a5c291/audio/128/default.mp3?aid=rss_feed&awCollectionId=1d8e143b-904e-45be-b6c5-8fba793d9d74&awEpisodeId=b64fab67-3153-4fd2-acd7-41f917a5c291&feed=GlfUTtJq","summary":"This podcast includes a discussion on what oncology pharmacists need to know about the role, efficacy, and safety of agents targeting BCMA in the personalized care of patients with multiple myeloma after disease progression on 1 or 2 previous lines of therapy.","meta_description":"This podcast includes a discussion on what oncology pharmacists need to know about the role, efficacy, and safety of agents targeting BCMA in the personal…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1713,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/what-oncology-pharmacists-need-to-know-about-targeting-bcma-in-early-relapsed-refractory-myeloma/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/what-oncology-pharmacists-need-to-know-about-targeting-bcma-in-early-relapsed-refractory-myeloma.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}